Growth Metrics

Novartis Ag (NVS) EBIT Margin (2016 - 2025)

Historic EBIT Margin for Novartis Ag (NVS) over the last 17 years, with Q4 2025 value amounting to 436.71%.

  • Novartis Ag's EBIT Margin rose 4098800.0% to 436.71% in Q4 2025 from the same period last year, while for Dec 2025 it was 536.94%, marking a year-over-year increase of 5080400.0%. This contributed to the annual value of 32.36% for FY2025, which is 34500.0% up from last year.
  • Novartis Ag's EBIT Margin amounted to 436.71% in Q4 2025, which was up 4098800.0% from 616.58% recorded in Q3 2025.
  • Novartis Ag's 5-year EBIT Margin high stood at 709.74% for Q1 2025, and its period low was 14.96% during Q3 2023.
  • Moreover, its 5-year median value for EBIT Margin was 24.68% (2021), whereas its average is 129.2%.
  • As far as peak fluctuations go, Novartis Ag's EBIT Margin crashed by -94200bps in 2022, and later soared by 6812300bps in 2025.
  • Quarter analysis of 5 years shows Novartis Ag's EBIT Margin stood at 19.37% in 2021, then dropped by -14bps to 16.59% in 2022, then skyrocketed by 36bps to 22.6% in 2023, then increased by 19bps to 26.84% in 2024, then surged by 1527bps to 436.71% in 2025.
  • Its last three reported values are 436.71% in Q4 2025, 616.58% for Q3 2025, and 454.15% during Q2 2025.